At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 106 enrolled
Drug / intervention
Tolterodine tartrate extended release capsules +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-centre, Double-blind, Randomised Trial Investigating the Efficacy and Safety of a Combination Therapy, Desmopressin and Tolterodine, for Treatment of Overactive Bladder With Nocturia in Women
In Brief
A Phase 2 clinical trial evaluating Tolterodine tartrate extended release capsules, Desmopressin orally disintegrating tablets, and 1 other intervention for Overactive Bladder. Completed, enrolled 106 participants across 24 sites.
Detailed Summary
The purpose of the trial is to investigate the efficacy of combining tolterodine and desmopressin compared with tolterodine monotherapy in the treatment of women with overactive bladder with nocturia in terms of reduction of nocturnal voids during 3 months of treatment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartJan 2013
Primary CompletionNov 2014
TodayJul 2026
First PostedNov 20, 2012
Enrollment StartJan 1, 2013
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.6 years ago
Interventions
Tolterodine tartrate extended release capsulesdrug
Desmopressin orally disintegrating tabletsdrug
Placebo orally disintegrating tabletsdrug